What are the potential risks of using lurbinectedin during pregnancy?

What happens to fetal development when lurbinectedin crosses the placenta?

Lurbinectedin is an alkylating agent that binds DNA minor grooves and inhibits transcription. It disrupts rapidly dividing cells, so fetal exposure during periods of organogenesis can produce malformations or embryonic death. Animal studies show increased rates of external, soft-tissue, and skeletal malformations when the drug is administered during early gestation.

Why do guidelines advise against lurbinectedin in pregnancy?

Current prescribing information states that lurbinectedin is contraindicated during pregnancy. The FDA label requires women of childbearing potential to use effective contraception during treatment and for at least three months after the last dose. Men with partners of childbearing potential are advised to use effective contraception for four months after their last dose.

What happens when a woman becomes pregnant while on lurbinectedin?

No human pregnancy data are available. If exposure occurs, clinicians typically recommend immediate discontinuation and referral to a maternal-fetal medicine specialist. Monitoring focuses on serial ultrasounds to assess fetal growth and malformation screening at 18–22 weeks.

Can lurbinectedin affect fertility?

Preclinical data indicate possible impairment of male and female fertility. The drug affects gonadal tissue, which has high cell-turnover rates. Clinical reports of permanent infertility are limited, but patients are advised to discuss fertility preservation options before starting therapy.

How long does lurbinectedin remain in the body after treatment ends?

The terminal half-life is approximately four days. Based on five half-lives, the drug is largely eliminated within three weeks. However, DNA adducts may persist longer than plasma clearance, DNA-binding effects could remain active until new cells are produced.

Why are companies challenging this patent?

Lurbinectedin is protected by composition-of-matter and method-of-use patents. Generic manufacturers have filed Paragraph IV challenges asserting invalidity or non-patentability. Challenges focus on obviousness relative to prior-art trabectedin analogs and on the claimed formulation.